{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:42:05Z","timestamp":1790948525692,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2407-11-510","type":"journal-article","created":{"date-parts":[[2011,12,7]],"date-time":"2011-12-07T21:28:01Z","timestamp":1323293281000},"source":"Crossref","is-referenced-by-count":13,"title":["A phase II study evaluating neo-\/adjuvant EIA chemotherapy, surgical resection and radiotherapy in high-risk soft tissue sarcoma"],"prefix":"10.1186","volume":"11","author":[{"given":"Thomas","family":"Schmitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkhard","family":"Lehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bischof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Falk","family":"Roeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Dimitrakopoulou-Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwig G","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunhild","family":"Mechtersheimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Wuchter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlinde","family":"Egerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,12,7]]},"reference":[{"key":"2984_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer statistics 2004. CA Cancer J Clin. 2004, 54: 8-29. 10.3322\/canjclin.54.1.8.","journal-title":"CA Cancer J Clin"},{"key":"2984_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/00000658-198704000-00003","volume":"4","author":"W Lawrence","year":"1987","unstructured":"Lawrence W, Donegan WL, Natarajan N, Mettlin C, Beart R, Winchester D: Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987, 4: 349-359.","journal-title":"Ann Surg"},{"key":"2984_CR3","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1200\/JCO.1996.14.5.1679","volume":"14","author":"PW Pisters","year":"1996","unstructured":"Pisters PW, Leung DH, Woodruff J, Shi W, Brennan MF: Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol. 1996, 14: 1679-1689.","journal-title":"J Clin Oncol"},{"key":"2984_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1053\/ejso.2001.1242","volume":"28","author":"PD Stefanovski","year":"2002","unstructured":"Stefanovski PD, Bidoli E, De Paoli A, Buonadonna A, Boz G, Libra M, Morassut S, Rossi C, Carbone A, Frustaci S: Prognostic factors in soft tissue sarcomas: A study of 395 patients. Eur J Surg Oncol. 2002, 28: 153-164. 10.1053\/ejso.2001.1242.","journal-title":"Eur J Surg Oncol"},{"key":"2984_CR5","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/cncr.11365","volume":"97","author":"GK Zagars","year":"2003","unstructured":"Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Evans HL: Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: An analysis of 1225 patients. Cancer. 2003, 97: 2530-2543. 10.1002\/cncr.11365.","journal-title":"Cancer"},{"key":"2984_CR6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/0959-8049(94)90286-0","volume":"30","author":"AN Wilson","year":"1994","unstructured":"Wilson AN, Davis A, Bell RS, O'Sullivan B, Catton C, Madadi F, Kandel R, Fornasier VL: Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer. 1994, 30: 746-751. 10.1016\/0959-8049(94)90286-0.","journal-title":"Eur J Cancer"},{"key":"2984_CR7","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/0360-3016(95)00105-8","volume":"32","author":"DA Fein","year":"1995","unstructured":"Fein DA, Lee WR, Lanciano RM, Corn BW, Herbert SH, Hanlon AL, Hoffman JP, Eisenberg BL, Coia LR: Management of extremity soft tissue sarcomas with limb-sparing surgery and postoperative irradiation: do total dose, overall treatment time, and the surgery-radiotherapy interval impact on local control?. Int J Radiat Oncol Biol Phys. 1995, 32: 969-976. 10.1016\/0360-3016(95)00105-8.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2984_CR8","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(02)09292-9","volume":"359","author":"B O'Sullivan","year":"2002","unstructured":"O'Sullivan B, Davis AM, Turcotte R, Bell R, Catton C, Chabot P, Wunder J, Kandel R, Goddard K, Sadura A, Pater J, Zee B: Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002, 359: 2235-2241. 10.1016\/S0140-6736(02)09292-9.","journal-title":"Lancet"},{"key":"2984_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1634\/theoncologist.10-10-833","volume":"10","author":"S Sleijfer","year":"2005","unstructured":"Sleijfer S, Seynaeve C, Verweij J: Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist. 2005, 10: 833-841. 10.1634\/theoncologist.10-10-833.","journal-title":"Oncologist"},{"key":"2984_CR10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009, 45: 228-247. 10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"2984_CR11","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2006.09.7717","volume":"25","author":"P Lorigan","year":"2007","unstructured":"Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, Radford JA, Van Glabbeke MM, Kirkpatrick A, Hogendoorn PC, Blay J: Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 2007, 25: 3144-3150. 10.1200\/JCO.2006.09.7717.","journal-title":"J Clin Oncol"},{"key":"2984_CR12","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1200\/JCO.1998.16.4.1438","volume":"16","author":"P Reichardt","year":"1998","unstructured":"Reichardt P, Tilgner J, Hohenberger P, D\u00f6rken B: Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol. 1998, 16: 1438-1443.","journal-title":"J Clin Oncol"},{"key":"2984_CR13","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1038\/bmt.2009.333","volume":"45","author":"B Kasper","year":"2010","unstructured":"Kasper B, Scharrenbroich I, Schmitt T, Wuchter P, Dietrich S, Ho AD, Egerer G: Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. Bone Marrow Transplant. 2010, 45: 1234-1238. 10.1038\/bmt.2009.333.","journal-title":"Bone Marrow Transplant"},{"key":"2984_CR14","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1016\/S0959-8049(01)00183-6","volume":"37","author":"RD Issels","year":"2001","unstructured":"Issels RD, Abdel-Rahman S, Wendtner C, Falk MH, Kurze V, Sauer H, Aydemir U, Hiddemann W: Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer. 2001, 37: 1599-1608. 10.1016\/S0959-8049(01)00183-6.","journal-title":"Eur J Cancer"},{"key":"2984_CR15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/S1470-2045(10)70071-1","volume":"11","author":"RD Issels","year":"2010","unstructured":"Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, Vujaskovic Z, Wessalowski R, Jauch KW, D\u00fcrr HR, Ploner F, Baur-Melnyk A, Mansmann U, Hiddemann W, Blay JY, Hohenberger P, European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG), European Society for Hyperthermic Oncology (ESHO): Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010, 11: 561-570. 10.1016\/S1470-2045(10)70071-1.","journal-title":"Lancet Oncol"},{"key":"2984_CR16","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2008.07.037","volume":"44","author":"M Schlemmer","year":"2008","unstructured":"Schlemmer M, Reichardt P, Verweij J, Hartmann JT, Judson I, Thyss A, Hogendoorn PC, Marreaud S, Van Glabbeke M, Blay JY: Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2008, 44: 2433-2436. 10.1016\/j.ejca.2008.07.037.","journal-title":"Eur J Cancer"},{"key":"2984_CR17","doi-asserted-by":"publisher","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","volume":"26","author":"N Penel","year":"2008","unstructured":"Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, Fournier C, Taieb S, Jimenez M, Isambert N, Peyrade F, Chevreau C, Bompas E, Brain EG, Blay JY: Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008, 26: 5269-5274. 10.1200\/JCO.2008.17.3146.","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"2984_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/BF00625047","volume":"106","author":"M Salzer-Kuntschik","year":"1983","unstructured":"Salzer-Kuntschik M, Delling G, Beron G, Sigmund R: Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80. J Cancer Res Clin Oncol. 1983, 106 (Suppl): 21-24.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2984_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/01.sla.0000152663.61348.6f","volume":"241","author":"MH Schwarzbach","year":"2005","unstructured":"Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, Willeke F, Cardona S, Mechtersheimer G, Lehnert T, Strauss LG, Herfarth C, Buchler MW: Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas. Ann Surg. 2005, 241: 286-294. 10.1097\/01.sla.0000152663.61348.6f.","journal-title":"Ann Surg"},{"key":"2984_CR20","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003, 13: 176-181. 10.1016\/S1053-4296(03)00031-6.","journal-title":"Semin Radiat Oncol"},{"key":"2984_CR21","doi-asserted-by":"publisher","first-page":"551","DOI":"10.2967\/jnumed.109.070862","volume":"51","author":"A Dimitrakopoulou-Strauss","year":"2010","unstructured":"Dimitrakopoulou-Strauss A, Strauss LG, Egerer G, Vasamiliette J, Mechtersheimer G, Schmitt T, Lehner B, Haberkorn U, Stroebel P, Kasper B: Impact of dynamic 18 F-FDG PET on the early prediction of therapy outcome in patients with high-risk soft-tissue sarcomas after neoadjuvant chemotherapy: a feasibility study. J Nucl Med. 2010, 51: 551-558. 10.2967\/jnumed.109.070862.","journal-title":"J Nucl Med"},{"key":"2984_CR22","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/cncr.25621","volume":"117","author":"A Carneiro","year":"2011","unstructured":"Carneiro A, Bendahl PO, Engellau J, Domanski HA, Fletcher CD, Rissler P, Rydholm A, Nilbert M: A prognostic model for soft tissue sarcoma of the extremities and trunk wall based on size, vascular invasion, necrosis, and growth pattern. Cancer. 2011, 117: 1279-1287. 10.1002\/cncr.25621.","journal-title":"Cancer"},{"key":"2984_CR23","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1200\/JCO.20.3.791","volume":"20","author":"MW Kattan","year":"2002","unstructured":"Kattan MW, Leung DH, Brennan MF: Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002, 20: 791-796. 10.1200\/JCO.20.3.791.","journal-title":"J Clin Oncol"},{"key":"2984_CR24","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S0959-8049(01)00083-1","volume":"37","author":"E Gortzak","year":"2001","unstructured":"Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, van Geel AN, Ezzat A, Santoro A, Oosterhuis JW, van Glabbeke M, Kirkpatrick A, Verweij J, E.O.R.T.C. Soft Tissue Bone Sarcoma Group and the National Cancer Institute of Canada Clinical Trials Group\/Canadian Sarcoma Group: A randomised phase II study on neo-adjuvant chemotherapy for'high-risk' adult soft-tissue sarcoma. Eur J Cancer. 2001, 37: 1096-1103. 10.1016\/S0959-8049(01)00083-1.","journal-title":"Eur J Cancer"},{"key":"2984_CR25","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1093\/annonc\/mdh431","volume":"15","author":"SR Grobmyer","year":"2004","unstructured":"Grobmyer SR, Maki RG, Demetri GD, Mazumdar M, Riedel E, Brennan MF, Singer S: Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004, 15: 1667-1672. 10.1093\/annonc\/mdh431.","journal-title":"Ann Oncol"},{"key":"2984_CR26","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/cncr.23592","volume":"113","author":"N Pervaiz","year":"2008","unstructured":"Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M: A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008, 113: 573-581. 10.1002\/cncr.23592.","journal-title":"Cancer"},{"key":"2984_CR27","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1093\/annonc\/mdq238","volume":"21","author":"A Italiano","year":"2010","unstructured":"Italiano A, Delva F, Mathoulin-Pelissier S, Le Cesne A, Bonvalot S, Terrier P, Trassard M, Michels JJ, Blay JY, Coindre JM, Bui B: Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol. 2010, 21: 2436-2441. 10.1093\/annonc\/mdq238.","journal-title":"Ann Oncol"},{"issue":"suppl 15","key":"2984_CR28","first-page":"559s","volume":"26","author":"A Le Cesne","year":"2008","unstructured":"Le Cesne A, Van Glabbeke M, Woll PJ, Bramwell VH, Casali PG, Hoekstra HJ, Reichardt P, Hogendoorn PC, Hohenberger P, Blay JY: The end of adjuvant chemotherapy era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma: Pooled analysis of the two STBSG-EORTC phase III clinical trials [abstract]. J Clin Oncol. 2008, 26 (suppl 15): 559s-","journal-title":"J Clin Oncol"},{"key":"2984_CR29","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1002\/cncr.25350","volume":"116","author":"WG Kraybill","year":"2010","unstructured":"Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B: Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer. 2010, 116: 4613-4621. 10.1002\/cncr.25350.","journal-title":"Cancer"},{"key":"2984_CR30","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1002\/cncr.25271","volume":"116","author":"TR Donahue","year":"2010","unstructured":"Donahue TR, Kattan MW, Nelson SD, Tap WD, Eilber FR, Eilber FC: Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram. Cancer. 2010, 116: 3883-3891. 10.1002\/cncr.25271.","journal-title":"Cancer"},{"key":"2984_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.ijrobp.2009.03.015","volume":"76","author":"DM MacDermed","year":"2010","unstructured":"MacDermed DM, Miller LL, Peabody TD, Simon MA, Luu HH, Haydon RC, Montag AG, Undevia SD, Connell PP: Primary tumor necrosis predicts distant control in locally advanced soft-tissue sarcomas after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010, 76: 1147-1153. 10.1016\/j.ijrobp.2009.03.015.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2984_CR32","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1245\/s10434-010-0997-0","volume":"17","author":"CY Liu","year":"2010","unstructured":"Liu CY, Yen CC, Chen WM, Chen TH, Chen PC, Wu HT, Shiau CY, Wu YC, Liu CL, Tzeng CH: Soft tissue sarcoma of extremities: the prognostic significance of adequate surgical margins in primary operation and reoperation after recurrence. Ann Surg Oncol. 2010, 17: 2102-2111. 10.1245\/s10434-010-0997-0.","journal-title":"Ann Surg Oncol"},{"key":"2984_CR33","volume-title":"J Surg Res","author":"W Tseng","year":"2010","unstructured":"Tseng W, Martinez SR, Tamurian RM, Borys D, Canter RJ: Histologic Type Predicts Survival in Patients with Retroperitoneal Soft Tissue Sarcoma. J Surg Res. 2010,"},{"issue":"suppl 2","key":"2984_CR34","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1634\/theoncologist.13-S2-32","volume":"13","author":"SM Schuetze","year":"2008","unstructured":"Schuetze SM, Baker LH, Benjamin RS, Canetta R: Selection of response criteria for clinical trials of sarcoma treatment. Oncologist. 2008, 13 (suppl 2): 32-40.","journal-title":"Oncologist"},{"issue":"suppl 2","key":"2984_CR35","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1634\/theoncologist.13-S2-14","volume":"13","author":"CC Jaffe","year":"2008","unstructured":"Jaffe CC: Response assessment in clinical trials: implications for sarcoma clinical trial design. Oncologist. 2008, 13 (suppl 2): 14-18.","journal-title":"Oncologist"},{"key":"2984_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/cncr.20769","volume":"103","author":"SM Schuetze","year":"2005","unstructured":"Schuetze SM, Rubin BP, Vernon C, Hawkins DS, Bruckner JD, Conrad EU, Eary JF: Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005, 103: 339-348. 10.1002\/cncr.20769.","journal-title":"Cancer"},{"key":"2984_CR37","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1158\/1078-0432.CCR-08-2537","volume":"15","author":"MR Benz","year":"2009","unstructured":"Benz MR, Czernin J, Allen-Auerbach MS, Tap WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps ME, Weber WA, Eilber FC: FDG-PET\/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. Clin Cancer Res. 2009, 15: 2856-2863. 10.1158\/1078-0432.CCR-08-2537.","journal-title":"Clin Cancer Res"},{"key":"2984_CR38","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/jmri.21358","volume":"27","author":"O Dudeck","year":"2008","unstructured":"Dudeck O, Zeile M, Pink D, Pech M, Tunn PU, Reichardt P, Ludwig WD, Hamm B: Diffusion-weighted magnetic resonance imaging allows monitoring of anticancer treatment effects in patients with soft-tissue sarcomas. J Magn Reson Imaging. 2008, 27: 1109-1113. 10.1002\/jmri.21358.","journal-title":"J Magn Reson Imaging"},{"key":"2984_CR39","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"S Sleijfer","year":"2009","unstructured":"Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Sch\u00f6ffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY: Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009, 27: 3126-3132. 10.1200\/JCO.2008.21.3223.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-510.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-510\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T10:58:08Z","timestamp":1497956288000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2984"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-510","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"article-number":"510"}}